KR20210076875A - 신생혈관형성인자의 억제를 위한 화합물 및 그 용도 - Google Patents

신생혈관형성인자의 억제를 위한 화합물 및 그 용도 Download PDF

Info

Publication number
KR20210076875A
KR20210076875A KR1020200176125A KR20200176125A KR20210076875A KR 20210076875 A KR20210076875 A KR 20210076875A KR 1020200176125 A KR1020200176125 A KR 1020200176125A KR 20200176125 A KR20200176125 A KR 20200176125A KR 20210076875 A KR20210076875 A KR 20210076875A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
hydroxy
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020200176125A
Other languages
English (en)
Korean (ko)
Inventor
강병헌
김소연
윤남구
이창욱
박동호
Original Assignee
주식회사 스마틴바이오
울산과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 스마틴바이오, 울산과학기술원 filed Critical 주식회사 스마틴바이오
Publication of KR20210076875A publication Critical patent/KR20210076875A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020200176125A 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도 Pending KR20210076875A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190168238 2019-12-16
KR20190168238 2019-12-16

Publications (1)

Publication Number Publication Date
KR20210076875A true KR20210076875A (ko) 2021-06-24

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200176125A Pending KR20210076875A (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Country Status (9)

Country Link
US (1) US12545695B2 (https=)
EP (1) EP4079309A4 (https=)
JP (1) JP7831775B2 (https=)
KR (1) KR20210076875A (https=)
CN (1) CN114901290B (https=)
AU (1) AU2020409912A1 (https=)
BR (1) BR112022011147A2 (https=)
CA (1) CA3164800A1 (https=)
WO (1) WO2021125800A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022265178A1 (ko) * 2021-06-15 2022-12-22 주식회사 스마틴바이오 Trap1 억제제 및 이의 용도
WO2024128829A1 (ko) * 2022-12-15 2024-06-20 주식회사 스마틴바이오 Trap-1 억제제

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
BRPI1014978A2 (pt) 2009-04-17 2019-07-02 Colby Pharmaceutical Company método de tratamento do câncer e composição farmacêutica.
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
[1] Kellen L. Meadows and Herbert I. Hurwitz, Anti-VEGF Therapies in the Clinic, Cold Spring Harb Perspect Med. 2012 Oct 1;2(10).
[10] Ionica Masgras, Carlos Sanchez-Martin, Giorgio Colombo and Andrea Rasola, The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells, Front Oncol. 2017 Mar 29;7:58.
[11] Verba KA, Wang RY, Arakawa A, Liu Y, Shirouzu M, Yokoyama S, and Agard DA, Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase, Science. 2016 Jun 24;352(6293):1542-7.
[2] Katja Zirlik and Justus Duyster, Anti-Angiogenics: Current Situation and Future Perspectives, Oncol Res Treat. 2018;41(4):166-171.
[3] Patrick Chames, Marc Van Regenmortel, Etienne Weiss and Daniel Baty, Therapeutic antibodies: successes, limitations and hopes for the future, Br J Pharmacol. 2009 May;157(2):220-33.
[4] T Kamba and DM McDonald, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer. 2007 Jun 18;96(12):1788-95.
[5] Peter A. Campochiaro, Ocular Neovascularization, J Mol Med (Berl). 2013 March ; 91(3): 311-321.
[6] Barbara Onnis, Annamaria Rapisarda and Giovanni Melillo, Development of HIF-1 inhibitors for cancer therapy, J. Cell. Mol. Med. Vol 13, No 9A, 2009 pp. 2780-2786.
[7] Young Chan Chae, M. Cecilia Caino, Sofia Lisanti, and et al. Control of Tumor Bioenergetics and Survival Stress Signaling by Mitochondrial HSP90s, Cancer Cell. 2012 Sep 11;22(3):331-44.
[8] Stuart K. Calderwood and Thomas L. Prince, Chaperones: Methods and Protocols, Humana Press, 2018, pp. 424-432.
[9] Daniel T. Gewirth, Paralog specific Hsp90 Inhibitors - a brief history and a bright future, Curr Top Med Chem. 2016 ; 16(25): 2779-2791.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022265178A1 (ko) * 2021-06-15 2022-12-22 주식회사 스마틴바이오 Trap1 억제제 및 이의 용도
WO2024128829A1 (ko) * 2022-12-15 2024-06-20 주식회사 스마틴바이오 Trap-1 억제제
KR20240093087A (ko) 2022-12-15 2024-06-24 주식회사 스마틴바이오 Trap-1 억제제

Also Published As

Publication number Publication date
WO2021125800A1 (ko) 2021-06-24
AU2020409912A1 (en) 2022-06-16
JP7831775B2 (ja) 2026-03-17
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
US12545695B2 (en) 2026-02-10
CA3164800A1 (en) 2021-06-24
US20230088747A1 (en) 2023-03-23
EP4079309A4 (en) 2024-01-10
JP2023506838A (ja) 2023-02-20
CN114901290B (zh) 2024-09-03
BR112022011147A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
JP6994538B2 (ja) 医薬化合物
KR102740623B1 (ko) Hpk1 억제제 및 이의 사용 방법
US10287252B2 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
KR102220175B1 (ko) 헤테로사이클릭 글루타미나아제 억제제
TWI571468B (zh) 蛋白質酪胺酸激酶活性抑制劑
CN102971312B (zh) 吡咯取代的2-二氢吲哚酮衍生物、其制备方法及用途
TW200940549A (en) Inhibitors of protein tyrosine kinase activity
WO2016026772A1 (en) Pharmaceutical compound
US12545695B2 (en) Compounds for inhibiting neovascularization factors and use thereof
WO2015082499A2 (en) Pharmaceutical compound
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
US20200268736A1 (en) Compositions and methods for treating inflammatory bowel disease
EP3765460A1 (en) Inhibition of bmp signaling, compounds, compositions and uses thereof
JP2009522363A (ja) プロテインキナーゼの阻害剤
CN114390924B (zh) 用于蛋白质降解的化合物、组合物和方法
JP6052685B2 (ja) α２アドレナリン受容体の調節因子としてのＮ−（イミダゾリジン−２−イリデン）−ヘテロシクロペンタ［ｂ］ピリジン誘導体
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
WO2014158302A1 (en) Novel sphingosine 1-phosphate receptor antagonists
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도
JP7766885B2 (ja) Ｔｒａｐ１阻害剤およびその用途
KR20220167944A (ko) Trap-1 억제제의 안과질환 치료 용도

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902